Structure-Based Virtual Screening for Novel Modulators of Human Orexin 2 Receptor with Cloud Systems and Supercomputers

Narcolepsy is a chronic neurologic disease characterized by excessive and inappropriate daytime sleepiness. Its pathophysiology is closely associated with the neuropeptide orexin, the absence of which is now believed to be responsible for most of the symptoms of the disease. Currently, no therapeutics against narcolepsy are available and afflicted patients are treated only symptomatically. Therefore, development of small-molecules able to penetrate into the brain and activate the orexin receptors represents a hopeful way. In this work we describe a computational approach which applies structure-based virtual screening of 1 million ligands to find novel potential modulators of orexin 2 receptor (OX2R). So-called rational computer-aided search for OX2R modulators was performed on a software-as-a-service (SaaS) cloud platform using iDock molecular docking program as a virtual screening engine. The results of the cloud-based calculations with iDock are analyzed and compared with the results of high-throughput flexible molecular docking in AutoDock Vina employing a pleasingly parallelized computation scheme on a peta-flops-scale supercomputer.

[1]  J. Topliss,et al.  A manual method for applying the Hansch approach to drug design. , 1977, Journal of medicinal chemistry.

[2]  Hugo Kubinyi,et al.  Success Stories of Computer‐Aided Design , 2006 .

[3]  Atsushi Nakagawa,et al.  Orexin‐A is composed of a highly conserved C‐terminal and a specific, hydrophilic N‐terminal region, revealing the structural basis of specific recognition by the orexin‐1 receptor , 2006, Journal of peptide science : an official publication of the European Peptide Society.

[4]  K. Waisser,et al.  QSAR study of antimycobacterial activity of quaternary ammonium salts of piperidinylethyl esters of alkoxysubstituted phenylcarbamic acids , 2008, Folia Microbiologica.

[5]  H. Rickards,et al.  Narcolepsy: a review , 2011, Neuropsychiatric disease and treatment.

[6]  Kwong-Sak Leung,et al.  idock: A multithreaded virtual screening tool for flexible ligand docking , 2012, 2012 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB).

[7]  C S Leonard,et al.  Orexin/hypocretin receptor signalling cascades , 2014, British journal of pharmacology.

[8]  Kwong-Sak Leung,et al.  istar: A Web Platform for Large-Scale Protein-Ligand Docking , 2014, PloS one.

[9]  Edward W. Lowe,et al.  Computational Methods in Drug Discovery , 2014, Pharmacological Reviews.

[10]  P. Kolb,et al.  Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant , 2014, Nature.

[11]  Kamil Kuca,et al.  Parallel Flexible Molecular Docking in Computational Chemistry on High Performance Computing Clusters , 2015, ICCCI.

[12]  Philip C Biggin,et al.  Discovery of the First Selective, Nonpeptidic Orexin 2 Receptor Agonists. , 2015, Journal of medicinal chemistry.